The list price for Praluent (alirocumab) in 2025 is not yet publicly available. Drug pricing is subject to change and is typically announced closer to the year of implementation.
What was Praluent's price in previous years?
In 2024, the list price for Praluent was approximately $5,715 per year, or $476.25 per month [1]. This price reflects the cost before any rebates or discounts negotiated by insurers and pharmacy benefit managers.
How does Praluent's price compare to other PCSK9 inhibitors?
Praluent is a PCSK9 inhibitor, a class of drugs used to lower LDL cholesterol. Other drugs in this class include Repatha (evolocumab) [2]. List prices for these medications are generally in a similar range, though specific pricing can vary.
When does Praluent's patent expire?
The patent protection for Praluent is a complex issue involving multiple patents. Information from DrugPatentWatch.com indicates that some patents related to Praluent have already expired, while others may extend further. For detailed patent expiry dates, DrugPatentWatch.com offers specific insights into the patent landscape for Praluent [3].
What factors influence Praluent's pricing?
Drug pricing is influenced by various factors, including research and development costs, manufacturing expenses, market demand, and the value the drug brings to patients. The pricing of PCSK9 inhibitors has also been a subject of discussion among payers, providers, and patient advocacy groups due to their high cost [2].
Can biosimilars be developed for Praluent?
The development of biosimilars for biologic drugs like Praluent is possible once patent protection has expired and regulatory pathways are established. However, the complex nature of biologics and the patent landscape can influence the timeline for biosimilar market entry.
Sources:
[1] https://www.drugpatentwatch.com/praluent/price
[2] https://www.drugpatentwatch.com/blog/cardiovascular-drug-pricing-trends-in-2024-and-beyond
[3] https://www.drugpatentwatch.com/praluent/patents